Portrazza（necitumumab）

Lung cancer is a highly prevalent cancer in the world, with approximately 2 million new lung cancer patients and 1.2 million deaths each year, with a mortality rate of over 60%. Squamous non-small cell lung cancer can be further divided into squamous cell NSCLC and non-squamous cell NSCLC. PORTRAZZA is a monoclonal antibody that blocks the activity of the EGFR gene, which is commonly found in squamous NSCLC. PORTRAZZA achieves the purpose of clinical treatment of squamous non-small cell lung cancer by blocking the activity of the EGFR gene.

PORTRAZZA™ is used to treat patients with advanced metastatic squamous non-small cell lung cancer. It is recommended to be used in combination with “gemcitabine” and “cisplatin”.

Usage
Intravenous infusion, the recommended dose is 800 mg (one bottle) each time, infused on the 1st and 8th day of each week.

Dosage form and specifications
Injection: 800 mg/50 mL (16 mg/mL) solution.

Use in special populations
Breastfeeding: Do not breastfeed.
PORTRAZZA was approved by the U.S. FDA in November 2015 for use in combination with two other drugs to treat advanced metastatic squamous small cell lung cancer.